Charles A. Reinhart III

CIK 1470871 · View on SEC EDGAR ↗

Insider

First SEC filing: Aug. 24, 2009 · Latest: Aug. 24, 2009

On this page

Insider at

Insider transactions

0 buys (P) 0 sells (S) Net: $0 + 20 non-open-market transactions below last 12 months, based on the transactions shown below

Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted

20 other filings hidden
Date Ticker Code Shares Price Value Owned after Δ own A/D vs now
June 7, 2023 PCRX S 1,371 $37.86 $51,906 33,626 Direct -3.92% Disposed -36.6% (price as of 2026-08-21)
June 6, 2023 PCRX S 1,236 $38.99 $48,192 34,997 Direct -3.41% Disposed -38.5% (price as of 2026-08-21)
June 6, 2022 PCRX S 2,516 $61.37 $154,407 28,283 Direct -8.17% Disposed -60.9% (price as of 2026-08-21)
June 4, 2021 PCRX S 2,648 $61.04 $161,634 24,799 Direct -9.65% Disposed -60.7% (price as of 2026-08-21)
June 4, 2020 PCRX S 1,489 $46.33 $68,985 14,847 Direct -9.11% Disposed -48.2% (price as of 2026-08-21)
June 4, 2019 PCRX S 1,106 $42.91 $47,458 11,936 Direct -8.48% Disposed -44.1% (price as of 2026-08-21)
June 4, 2018 PCRX S 708 $33.02 $23,378 8,042 Direct -8.09% Disposed -27.3% (price as of 2026-08-21)

P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding

Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.

Derivative holdings (Form 4 Table II)

Options, RSUs and convertible securities reported on Form 4 Table II.

Date Ticker Security Underlying Exercise price Expiration Shares A/D
June 14, 2023 PCRX Stock Option (Right to Buy) Common Stock (22,500) $38.74 June 14, 2033 22,500 Acquired
June 8, 2022 PCRX Stock Option (Right to Buy) Common Stock (19,900) $59.39 June 8, 2032 19,900 Acquired
June 9, 2021 PCRX Stock Option (Right to Buy) Common Stock (15,000) $60.96 June 9, 2031 15,000 Acquired
June 9, 2020 PCRX Stock Option (Right to Buy) Common Stock (31,500) $47.65 June 9, 2030 31,500 Acquired
June 5, 2019 PCRX Stock Option (Right to Buy) Common Stock (26,300) $43.54 June 5, 2029 26,300 Acquired
June 13, 2018 PCRX Stock Option (Right to Buy) Common Stock (30,000) $38.35 June 13, 2028 30,000 Acquired
June 14, 2017 PCRX Stock Option (Right to Buy) Common Stock (17,500) $44.20 June 14, 2027 17,500 Acquired
Dec. 7, 2016 PCRX Stock Option (Right to Buy) Common Stock (16,000) $32.35 Dec. 7, 2026 16,000 Acquired
May 3, 2016 PCRX Stock Option (Right to Buy) Common Stock (70,000) $51.54 May 3, 2026 70,000 Acquired
Dec. 8, 2010 ALT Stock Options (right to buy) Common Stock (75,000) $3.55 Dec. 8, 2020 75,000 Acquired
May 6, 2010 ALT Stock Options (right to buy) Common Stock (50,000) $1.38 May 6, 2020 50,000 Acquired

Exercise/conversion price is blank when not applicable (e.g. RSUs).

Initial ownership (Form 3) 1 holding

Securities held when first becoming an insider, per SEC Form 3.

Date Ticker Security Shares Ownership
Aug. 24, 2009 ALT Employee stock option (right to buy)→ Common stock (200,000) 200,000 Direct

Compensation (DEF 14A)

Matched by name from proxy statements (DEF 14A) — verify against the filing.

ALT

Fiscal year Salary Bonus Stock awards Option awards Non-equity incentive Pension change Other Total
2010 $330,000 — — $248,750 $29,700 — $42,424 $650,874

PCRX

CFO
Fiscal year Salary Bonus Stock awards Option awards Non-equity incentive Pension change Other Total
2023 $486,671 $219,100 $348,660 $358,477 — — $14,520 $1,427,428
2022 $475,000 $290,000 $472,151 $498,495 — — $15,582 $1,751,228
2019 $433,512 $195,000 $191,576 $560,952 — — $8,704 $1,389,744

Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.